Massively parallel immunopeptidome by DNA sequencing provides insights into cancer antigen presentation



Summary

Massively parallel immunopeptidome sequencing (MPIS) uses DNA sequencing to identify peptides presented by MHC molecules on cell surfaces, offering a comprehensive view of antigen presentation. This powerful technique allows researchers to catalog thousands of immunopeptides, providing crucial insights into the antigens presented by cancer cells. Specifically, MPIS helps identify tumor-associated antigens (TAAs) and neoantigens, which are critical targets for immunotherapy. By characterizing the immunopeptidome, researchers can better understand tumor immune evasion mechanisms and develop more effective, personalized cancer treatments. This approach promises to accelerate the discovery of novel immunotherapeutic targets and improve patient outcomes.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!